Neurology Xagena
Two-year interim results from a Phase 2 trial comparing MabCampath ( Alemtuzumab; Campath ) with Rebif ( Interferon beta-1a ) for the treatment of multiple sclerosis have demonstrated statistically si ...
The results from the Lemtrada ( Alemtuzumab ) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing-remitting multiple sclerosis were published in The Lancet.In CARE-MS I and CARE-MS II, ...
Alemtuzumab ( Lemtrada ), an anti-CD52 monoclonal antibody, has increased the risk of thyroid dysfunction in CAMMS223, a phase 2 trial in relapsing-remitting multiple sclerosis. The objective of th ...
New magnetic resonance imaging ( MRI ) data from the Lemtrada ( Alemtuzumab ) clinical development program were presented at the 66th American Academy of Neurology ( AAN ) Annual Meeting. In Alemtuzu ...
Interim results from the second year of the extension study of Alemtuzumab ( Lemtrada ) for multiple sclerosis were presented at the European Committee for Research and Treatment in Multiple Sclerosis ...
The FDA ( Food and Drug Administration ) has approved Lemtrada ( Alemtuzumab ) for the treatment of patients with relapsing forms of multiple sclerosis ( MS ). Because of its safety profile, the use o ...
Roche has announced positive results from two pivotal studies evaluating the investigational medicine Ocrelizumab compared with Interferon beta-1a ( Rebif ), a standard-of-care therapy, in people with ...
New efficacy data for investigational Cladribine tablets were presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis ( ECTRIMS ), in London. The fi ...
Ocrelizumab ( Ocrevus ) was approved for the treatment of relapsing multiple sclerosis ( RMS ) and primary progressive multiple sclerosis ( PPMS ) by the FDA ( US Food and Drug Administration ) in Mar ...
